Comment on this story Comment During America’s renewed mania for book banning, I was disappointed that “Rule of the Bone” didn’t inspire more prigs to start collecting dry sticks. When it came out in 1995, Russell Banks’ graphic, drug-fueled novel about a troubled 14-year-old boy caused a predictable uproar. But now it’s not even on …
Tributes for Russell Banks, the American novelist who died on Saturday Read More »
ANONYMOUS SET of Mohsin Hamid’s 2022 novel The last white man brings with it a certain comfort. The British-Pakistani author’s lack of specificity is purposeful: thrust into a nameless city in an unknown country, the reader has no cultural foundations to cling to, no social baggage to carry. The blank slate leaves only one aspect …
Bret Easton Ellis’ need to revisit the setting of his debut novel Less Than Zero (1985)—the study of disaffected LA teenagers that made him famous before he turned 21—is increasingly perplexing. If Ellis had wanted to trade on past glory for commercial reasons, he would have written endless sequels to the book that turned him …
the author of American Psycho has run out of ideas Read More »
Crime writers of both sexes — from various countries — often grumble about the fact that America’s crime heavyweights (usually white, male, and late middle-aged) are accorded a gravitas that others struggle to achieve. But I’m afraid this column can’t help the grumblers this week because it begins with three novelists who fit that description …
The Return of Three American Masters — The Best New Crime Thrillers Read More »
Vincerx’s proprietary carrier and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significantly improved safety in non-human primates (NHPs) compared to Mylotarg™ (gemtuzumab ozogamicin). VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine …
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in AML xenograft models KT-253 showed combinatorial benefit with the BCL-2 inhibitor venetoclax in a model of venetoclax-resistant AML KT-253 is also active in other hematologic malignancies including DLBCL WATERTOWN, Massachusetts, Dec. 11, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, …
The oral presentation describes the unique library of APC nanobodies and its potential as a source for novel treatments of diseases including trauma, hemophilia, ischemia and sepsis. SAN FRANCISCO, Dec. 11, 2022 /PRNewswire/ — Coagulant Therapeutics Corporation, a privately held company focused on the design, development and commercialization of therapeutics targeting the coagulation cascade and …